Jefferies Global Healthcare Conference on
June 5 in New York
Goldman Sachs
45th Annual Global Healthcare Conference on June 13 in Miami
SAN DIEGO, May 29, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming
investor conferences in June.
- Kevin Gorman, Chief Executive
Officer, Kyle Gano, Chief Business
Development and Strategy Officer, and Matt
Abernethy, Chief Financial Officer will present at the
Jefferies Global Healthcare Conference at 2:30 p.m. Eastern Time on Wednesday June 5, 2024
in New York.
- Kevin Gorman and Kyle Gano will present at the Goldman Sachs
45th Annual Global Healthcare Conference at 10:40 a.m. Eastern Time on Thursday June 13, 2024
in Miami.
The live presentations will be webcast and may be accessed on
Neurocrine Biosciences' website under Investors at
www.neurocrine.com. A replay of the webcasts will be available on
the website approximately one hour after the conclusion of the
events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and
uterine fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn, X
(Formerly Twitter) and Facebook. (*in collaboration with
AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
The Neurocrine logo is a trademark of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-june-302157890.html
SOURCE Neurocrine Biosciences, Inc.